MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cncr.31187

Медицинская библиотека · Cancer · 2017

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.

Sasaki Koji, Kantarjian Hagop, O'Brien Susan, Ravandi Farhad, Konopleva Marina, Borthakur Gautam, Garcia-Manero Guillermo, Wierda William, Daver Naval, Ferrajoli Alessandra, Takahashi Koichi, Jain Preetesh, Rios Mary Beth, Pierce Sherry, Jabbour Elias, Cortes Jorge E

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

The achievement of a sustained deep molecular response is a goal of increasing relevance because it opens the possibility of treatment discontinuation. The objective of this analysis was to develop a prediction model for a sustained molecular response with BCR-ABL1 level <0.0032% on the international scale (MR4.5 ) for at least 2 years according to BCR-ABL1 levels achieved within the first 12 months of therapy.

METHODS

Data for 603 patients with newly diagnosed chronic myeloid leukemia in chronic phase in consecutive prospective clinical trials were analyzed. The best fit average molecular response was defined by robust linear regression models, with which the average molecular levels were defined. The minimum acceptable molecular response was defined by quantile regression for the 95th percentile, with which the worst 5% BCR-ABL1 levels were identified.

RESULTS

In 603 patients with a median follow-up of 103 months, 2002 BCR-ABL1-level data points within 1 year of tyrosine kinase inhibitors were identified. The regression equation for the best fit average levels for a sustained MR4.5 was Log10 (PCR) = -0.1424 × (Months) - 0.8668, and the regression equation for minimum acceptable levels was Log10 (PCR) = -0.1403 × (Months) + 0.6142 (where PCR indicates polymerase chain reaction). To achieve a sustained MR4.5 , the best fit average levels were 0.051%, 0.019%, 0.007%, and 0.003% at 3, 6, 9, and 12 months, respectively; the minimum acceptable levels were 1.561%, 0.592%, 0.225%, and 0.085% at 3, 6, 9, and 12 months, respectively.

CONCLUSIONS

This model proposes optimal values that predict the highest probability of reaching such a goal. These values can be used to guide therapy when a sustained MR4.5 is the objective. Cancer 2018;124:1160-8. © 2017 American Cancer Society.

Для цитирования: Sasaki Koji, Kantarjian Hagop, O'Brien Susan, Ravandi Farhad, Konopleva Marina, Borthakur Gautam, Garcia-Manero Guillermo, Wierda William, Daver Naval, Ferrajoli Alessandra, Takahashi Koichi, Jain Preetesh, Rios Mary Beth, Pierce Sherry, Jabbour Elias, Cortes Jorge E. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.. Cancer. 2017. DOI: 10.1002/cncr.31187.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.